FDA panel endorses Pfizer’s COVID-19 vaccine booster for people 65 and older, high-risk patients

A U.S. Food and Drug Administration (FDA) advisory panel on Friday endorsed emergency approval for the Pfizer-BioNTech COVID-19 vaccine booster shot at least six months following the second dose among people ages 65 and older and those at high risk of occupational exposure and severe COVID-19.The vote was 18–0. The vote will now go before the FDA to issue a final decision. The panel earlier Friday afternoon voted to reject licensure of Pfizer’s booster vaccine in people ages 16 and older, at a vote of 2–16.During the deliberations, panel members suggested older, vulnerable populations may benefit from boosters, but noted insufficient data among younger groups and concerns over potential increased risk for heart inflammation, particularly among males ages 16–17.CLICK HERE TO FIND A …

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Send this to a friend